Company formed to create first oral integrin therapies for wide range of diseases, leveraging new discoveries from the lab of Scientific Founder Tim Springer, Ph.D.
Here’s to the fact that all great things start the same.
Despite all of Tim Springer’s achievements – tributes, awards, companies, and other accomplishments – his latest philanthropic venture launches grand in vision but step-by-step and local in action.
Integration between biotech and Big Pharma has never before looked like this.
Both Astra Zeneca and Morphic Therapeutic decided to forego an originally planned divider wall. As far as we know, this creates the 1st completely integrated labs between Big Pharma and Biotech leading to valued personal interaction; and sharing of ideas, equipment, and resources.
A Pot of Gold.
I was looking into Novel Targets at Merck about a year ago, specifically for diabetic retinopathy. I became very excited about integrins as potential targets for diabetic retinopathy and age-related macular degeneration.
In this video, CEO Praveen Tpirneni explains what he found most surprising in Series A fundraising for Morphic Therapeutic.
Over the last 20 years there has been major innovation in treatment of Inflammatory Bowel Disease (IBD) catalyzed due the biologics that offer greater on target selectivity than aminosalicylates, corticosteroids or immunosupressants.
In today’s capital efficient environment, why would Morphic decide to bring crystallography capabilities in-house?